专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130109010A1 METHOD FOR DETECTION OF INFECTION WITH HUMAN CYTOMEGALOVIRUS 审中-公开
标题翻译：用人类细胞病毒检测感染的方法
公开(公告)号：US20130109010A1
公开(公告)日：2013-05-02
申请号：US13808465
申请日：2011-07-05
申请人： Nobuyuki Fujii , Hideo Honda , Yoshiaki Uchida , Kazuya Omi
发明人： Nobuyuki Fujii , Hideo Honda , Yoshiaki Uchida , Kazuya Omi
IPC分类号： G01N33/68
CPC分类号： G01N33/6854 , C07K14/005 , C12N2710/16122 , G01N33/56994 , G01N2333/045 , G01N2469/20
摘要： A novel means by which HCMV infection can be detected with a high sensitivity and whose practicality is high is disclosed. The present inventors synthesized as many as 15 kinds of HCMV proteins in their full length forms, and intensively studied their reactivities with sera from HCMV-infected patients to find that all the infected patients can be detected without fail when using the pp28 full length protein as an antigen. The pp28 full length protein can be synthesized and purified as a recombinant protein in a large scale by using Escherichia coli, and can be commercially used as an antigen for HCMV tests.
摘要翻译：公开了一种以高灵敏度检测HCMV感染并且其实用性高的新颖手段。本发明人以其全长形式合成了多达15种HCMV蛋白，并且深入研究了与HCMV感染患者的血清的反应性，发现使用pp28全长蛋白时所有感染的患者都可以被检测到，抗原。通过使用大肠杆菌可以大量合成和纯化pp28全长蛋白质作为重组蛋白质，并且可以商业上用作HCMV测试的抗原。

2. 发明授权

US09599608B2 Antibody against affinity complex 有权
公开(公告)号：US09599608B2
公开(公告)日：2017-03-21
申请号：US14346615
申请日：2012-07-04
申请人： Kazuya Omi , Tsuyoshi Ando , Yoshiaki Uchida , Katsutoshi Goishi , Yoshie Goishi , Asako Oka , Takashi Shirakawa , Takuya Sakyu
发明人： Kazuya Omi , Tsuyoshi Ando , Yoshiaki Uchida , Katsutoshi Goishi , Asako Oka , Takashi Shirakawa , Takuya Sakyu
IPC分类号： C07K16/44 , C07K16/26 , G01N33/543 , G01N33/531 , G01N33/74 , G01N33/78 , G01N33/82
CPC分类号： G01N33/54306 , C07K16/26 , C07K16/44 , C07K2317/24 , C07K2317/32 , C07K2317/92 , G01N33/531 , G01N33/743 , G01N33/78 , G01N33/82
摘要： The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).

3. 发明申请

US20130029357A1 DIAGNOSTIC MARKER FOR EFFECT OF ANTICANCER AGENT 有权
标题翻译：诊断标签对抗原剂的影响
公开(公告)号：US20130029357A1
公开(公告)日：2013-01-31
申请号：US13635911
申请日：2011-03-18
申请人： Nobuyuki Ise , Daisuke Nambara , Kazuya Omi
发明人： Nobuyuki Ise , Daisuke Nambara , Kazuya Omi
IPC分类号： G01N33/573
CPC分类号： C07K16/2863 , C12Q1/485 , G01N33/5011 , G01N33/566 , G01N33/574 , G01N33/57423 , G01N33/57492 , G01N2500/00 , G01N2800/44 , G01N2800/52
摘要： The present invention enables to realize a convenient determination of a therapeutic effect of an anticancer agent on a cancer. Specifically, the present invention provides a diagnostic marker for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET; a diagnostic reagent for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET and the fragment of the extracellular domain of c-MET; and a method of testing an effect of an anticancer agent on a cancer, comprising (a) measuring a concentration of a fragment of an extracellular domain of c-MET in a biological sample from a subject, and (b) comparing the measured concentration of the fragment of the extracellular domain of c-MET with an indicator which presents a relationship between a concentration of the fragment of the extracellular domain of c-MET and the effect of the anticancer agent on the cancer.
摘要翻译：本发明能够实现抗癌剂对癌症的治疗效果的方便的测定。具体地说，本发明提供了抗癌剂对癌症的作用的诊断标记物，其包含对c-MET细胞外结构域片段具有亲和性的物质; 用于抗癌剂对癌症的作用的诊断试剂，其包含对c-MET细胞外结构域片段和c-MET细胞外结构域片段具有亲和性的物质; 以及测试抗癌剂对癌症的作用的方法，包括（a）测量来自受试者的生物样品中c-MET的细胞外结构域的片段的浓度，和（b）将测量的浓度 c-MET的细胞外结构域的片段具有指示剂，其表现出c-MET细胞外结构域的片段的浓度与抗癌剂对癌症的作用之间的关系。

4. 发明申请

US20120202214A1 METHOD FOR DETECTING FUSION GENE 审中-公开
标题翻译：检测融合基因的方法
公开(公告)号：US20120202214A1
公开(公告)日：2012-08-09
申请号：US13500497
申请日：2010-09-28
申请人： Kazuya Omi
发明人： Kazuya Omi
IPC分类号： C12Q1/68 , G01N33/50 , G01N27/447 , C07H21/04 , G01N21/64
CPC分类号： C12Q1/6886 , C12Q2600/156 , C12Q2600/16
摘要： Disclosed is a means which enables simple and rapid detection of the presence of any fusion genes including even unknown fusion genes. The method for measuring a fusion gene(s) according to the present invention is applied to a sample separated from a living body, and comprises: measuring expressions of a 5′-region and a 3′-region of one of the component genes of the fusion gene(s) which may be present in the living body, wherein said 5′-region is upstream of and said 3′-region is downstream of a fusion point in said one of the component genes; and comparing the expression of the 5′-region with the expression of the 3′-region. The fusion gene to be measured is e.g. a fusion gene between ALK gene and another gene.
摘要翻译：公开了能够简单快速地检测任何融合基因（甚至未知的融合基因）的存在的方法。将根据本发明的融合基因的测定方法应用于从生物体分离的样品，并且包括：测定其中一个成分基因的5'区域和3'区域的表达可能存在于生物体中的融合基因，其中所述5'区域在所述一个组分基因中的融合点的上游并且所述3'-区域是融合点的下游; 并比较5'-区的表达与3'区的表达。要测量的融合基因是例如。 ALK基因与另一基因之间的融合基因。

5. 发明授权

US09157905B2 Method for identifying oncogene, method for establishing oncogene-expressing cell, and method of screening oncogene targeting drug 有权
标题翻译：确定致癌基因的方法，建立癌基因表达细胞的方法，以及筛选致癌基因靶向药物的方法
公开(公告)号：US09157905B2
公开(公告)日：2015-10-13
申请号：US13580207
申请日：2011-02-21
申请人： Nobuyuki Ise , Kazuya Omi , Daisuke Nambara
发明人： Nobuyuki Ise , Kazuya Omi , Daisuke Nambara
IPC分类号： C12N15/00 , C12N15/86 , C12N15/87 , C12N5/00 , C12N5/071 , G01N33/50 , C12N5/09 , C12Q1/48
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2501/998 , C12Q1/48 , G01N33/5023
摘要： The present invention provides a methodology that can develop a more excellent anti-cancer drug than conventional ones for various cancers. Specifically, the present invention provides a method for establishing an artificial cell, comprising treating a cancer cell with an expression vector for a foreign oncogene and then culturing the cancer cell treated with the expression vector under a condition which inhibits an expression or function of an oncogene that is inherent to the cancer cell, and an established artificial cell; a method of screening an anti-cancer drug, comprising evaluating whether or not a test substance inhibits a proliferation of the artificial cell; as well as a method for identifying an oncogene, comprising treating a cancer cell with an expression vector for a test gene and then culturing the cancer cell treated with the expression vector under a condition which inhibits an expression or function of an oncogene that is inherent to the cancer cell.
摘要翻译：本发明提供了可以开发比常规的抗癌药物更优异的各种癌症的方法。具体地说，本发明提供一种建立人造细胞的方法，其特征在于，以外源癌基因的表达载体处理癌细胞，然后在抑制致癌基因的表达或功能的条件下培养用表达载体处理的癌细胞这是癌细胞固有的，以及已建立的人造细胞; 筛选抗癌药物的方法，包括评估测试物质是否抑制人造细胞的增殖; 以及用于鉴定致癌基因的方法，包括用测试基因的表达载体处理癌细胞，然后在抑制癌基因固有的癌基因的表达或功能的条件下培养用表达载体处理的癌细胞癌细胞。

6. 发明申请

US20120178085A1 METHOD FOR EVALUATION OF CULTURED CELLS, AND METHOD FOR SCREENING OF BIOMARKER 审中-公开
标题翻译：用于评估培养细胞的方法，以及用于生物标记筛选的方法
公开(公告)号：US20120178085A1
公开(公告)日：2012-07-12
申请号：US13381384
申请日：2010-06-25
申请人： Yoshiyuki Hotta , Kazuya Omi , Asako Oka
发明人： Yoshiyuki Hotta , Kazuya Omi , Asako Oka
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6881 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Q2600/178
摘要： Disclosed are novel means by which evaluation of cultured cells and screening of biomarkers can be attained without consuming the cultured cells. A method for evaluating cultured cells according to the present invention comprises culturing cells in a serum-free medium, and measuring at least one nucleic acid released from the cells into the culture medium. A method for screening of a biomarker according to the present invention comprises culturing cells in a serum-free medium, and measuring a nucleic acid(s) released from the cells into the culture medium. Nucleic acid used as an indicator is e.g. microRNA.
摘要翻译：公开的是通过其可以在不消耗培养细胞的情况下获得培养细胞的评价和生物标志物的筛选的新手段。根据本发明的用于评价培养细胞的方法包括在无血清培养基中培养细胞，并测量从细胞释放到培养基中的至少一种核酸。根据本发明的筛选生物标志物的方法包括在无血清培养基中培养细胞，并测量从细胞中释放到培养基中的核酸。用作指示剂的核酸是例如。 microRNA。

7. 发明授权

US09175084B2 Diagnostic marker for effect of anticancer agent 有权
标题翻译：抗癌剂效果的诊断标记
公开(公告)号：US09175084B2
公开(公告)日：2015-11-03
申请号：US13635911
申请日：2011-03-18
申请人： Nobuyuki Ise , Daisuke Nambara , Kazuya Omi
发明人： Nobuyuki Ise , Daisuke Nambara , Kazuya Omi
IPC分类号： A61K35/12 , C07K16/28 , G01N33/50 , G01N33/574 , C12Q1/48 , G01N33/566
CPC分类号： C07K16/2863 , C12Q1/485 , G01N33/5011 , G01N33/566 , G01N33/574 , G01N33/57423 , G01N33/57492 , G01N2500/00 , G01N2800/44 , G01N2800/52
摘要： The present invention enables to realize a convenient determination of a therapeutic effect of an anticancer agent on a cancer. Specifically, the present invention provides a diagnostic marker for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET; a diagnostic reagent for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET and the fragment of the extracellular domain of c-MET; and a method of testing an effect of an anticancer agent on a cancer, comprising (a) measuring a concentration of a fragment of an extracellular domain of c-MET in a biological sample from a subject, and (b) comparing the measured concentration of the fragment of the extracellular domain of c-MET with an indicator which presents a relationship between a concentration of the fragment of the extracellular domain of c-MET and the effect of the anticancer agent on the cancer.
摘要翻译：本发明能够实现抗癌剂对癌症的治疗效果的方便的测定。具体地说，本发明提供了抗癌剂对癌症的作用的诊断标记物，其包含对c-MET细胞外结构域片段具有亲和性的物质; 用于抗癌剂对癌症的作用的诊断试剂，其包含对c-MET细胞外结构域片段和c-MET细胞外结构域片段具有亲和性的物质; 以及测试抗癌剂对癌症的作用的方法，包括（a）测量来自受试者的生物样品中c-MET的细胞外结构域的片段的浓度，和（b）将测量的浓度 c-MET的细胞外结构域的片段具有指示剂，其表现出c-MET细胞外结构域的片段的浓度与抗癌剂对癌症的作用之间的关系。

8. 发明申请

US20120315628A1 METHOD FOR IDENTIFYING ONCOGENE, METHOD FOR ESTABLISHING ONCOGENE-EXPRESSING CELL, AND METHOD OF SCREENING ONCOGENE TARGETING DRUG 有权
标题翻译：用于鉴定ONCOGENE的方法，用于建立ONCOGENE表达细胞的方法和筛选ONCOGENE靶向药物的方法
公开(公告)号：US20120315628A1
公开(公告)日：2012-12-13
申请号：US13580207
申请日：2010-02-21
申请人： Nobuyuki Ise , Kazuya Omi , Daisuke Nambara
发明人： Nobuyuki Ise , Kazuya Omi , Daisuke Nambara
IPC分类号： C12N5/10 , C12Q1/18 , C12Q1/68 , C12N15/85
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2501/998 , C12Q1/48 , G01N33/5023
摘要： The present invention provides a methodology that can develop a more excellent anti-cancer drug than conventional ones for various cancers. Specifically, the present invention provides a method for establishing an artificial cell, comprising treating a cancer cell with an expression vector for a foreign oncogene and then culturing the cancer cell treated with the expression vector under a condition which inhibits an expression or function of an oncogene that is inherent to the cancer cell, and an established artificial cell; a method of screening an anti-cancer drug, comprising evaluating whether or not a test substance inhibits a proliferation of the artificial cell; as well as a method for identifying an oncogene, comprising treating a cancer cell with an expression vector for a test gene and then culturing the cancer cell treated with the expression vector under a condition which inhibits an expression or function of an oncogene that is inherent to the cancer cell.
摘要翻译：本发明提供了可以开发比常规的抗癌药物更优异的各种癌症的方法。具体地说，本发明提供一种建立人造细胞的方法，其特征在于，以外源癌基因的表达载体处理癌细胞，然后在抑制致癌基因的表达或功能的条件下培养用表达载体处理的癌细胞这是癌细胞固有的，以及已建立的人造细胞; 筛选抗癌药物的方法，包括评估测试物质是否抑制人造细胞的增殖; 以及用于鉴定致癌基因的方法，包括用测试基因的表达载体处理癌细胞，然后在抑制癌基因固有的癌基因的表达或功能的条件下培养用表达载体处理的癌细胞癌细胞。

9. 发明申请

US20120282633A1 ANTIBODY SPECIFIC TO ACTIVATED EGFR 审中-公开
标题翻译：抗体活化EGFR的特异性
公开(公告)号：US20120282633A1
公开(公告)日：2012-11-08
申请号：US13521942
申请日：2011-01-07
申请人： Nobuyuki Ise , Kazuya Omi
发明人： Nobuyuki Ise , Kazuya Omi
IPC分类号： C07K16/40 , G01N33/574 , G01N33/573
CPC分类号： C07K16/2863 , G01N2333/71
摘要： Disclosed is a means for accurately measuring activated EGFR regardless of whether phosphorylation has occurred or not. The antibody or antigen-binding fragment thereof according to the present invention can bind to activated EGFR regardless of whether the activated EGFR is in a phosphorylated form or in a nonphosphorylated form. By carrying out an immunoassay using the antibody or antigen-binding fragment thereof, activated EGFR in a sample can be measured more accurately than by conventional methods. Abnormal activation of EGFR is responsible for the onset of cancer, and is regarded as a therapeutic target. Therefore, the antibody or antigen-binding fragment thereof according to the present invention is also useful for detection of cancers, in particular, cancers to which a molecular target drug(s) whose target is EGFR is(are) to be administered.
摘要翻译：公开了用于精确测量活化的EGFR的方法，而不管是否发生磷酸化。根据本发明的抗体或其抗原结合片段可以结合活化的EGFR，而不管活化的EGFR是磷酸化形式还是非磷酸化形式。通过使用抗体或其抗原结合片段进行免疫测定，可以比常规方法更准确地测量样品中的活化EGFR。 EGFR的异常活化是癌症发病的原因，被认为是治疗靶点。因此，根据本发明的抗体或其抗原结合片段也可用于检测癌症，特别是其目标为EGFR的分子靶向药物被施用的癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式